Antibody-mediated blockade of phosphatidylserine enhances the anti-tumor activity of targeted therapy and immune checkpoint inhibitors by affecting myeloid and lymphocyte populations in the tumor microenvironment

Documenti analoghi

• Targeting phosphatidylserine synergizes with immune checkpoint blockade by inducing de novo tumor specific immunity
  di: Huang, Xianming, et al.
  Pubblicazione: (2015)
• Correlative studies of a Phase II clinical study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma
  di: Yopp, Adam, et al.
  Pubblicazione: (2014)
• Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of downstream immune checkpoint inhibition in K1735 mouse melanoma
  di: Huang, Xianming, et al.
  Pubblicazione: (2014)
• Targeting of phosphatidylserine by monoclonal antibodies reverses an immunosuppressive checkpoint inducing innate and specific anti-tumor responses
  di: Gong, Jian, et al.
  Pubblicazione: (2013)
• Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in breast tumors
  di: Gong, Jian, et al.
  Pubblicazione: (2014)